Clinical Care Information for COVID-19
Managing COVID-19 Patients
Highlights key COVID-19 clinical information for healthcare providers and provides selected links to full guidance.
EVUSHELDTM, a monoclonal antibody combination that was used for pre-exposure prophylaxis to protect against SARS-CoV-2 infection, is not currently authorized for emergency use in the United States until further notice by FDA. This is because it is unlikely to be active against certain SARS-CoV-2 variants. According to the most recent CDC Nowcast data, these variants are projected to be responsible for more than 90% of current infections in the U.S. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants. Healthcare facilities and providers with EVUSHELDTM should retain all products in the event that SARS-CoV-2 variants that are neutralized by EVUSHELDTM become more prevalent in the U.S. in the future. For more information, see FDA’s announcement. For questions about the announcement, Contact FDA.
Guidance by Patient Type
Healthcare providers who have cared or are caring for patients younger than 21 years of age meeting criteria for multisystem inflammatory syndrome in children (MIS-C) should report suspected cases to their local, state, or territorial health department.
For additional reporting questions, please contact CDC’s 24-hour Emergency Operations Center at 770-488-7100.
Names of specific vendors, manufacturers, or products in this collection of content are included for public health and informational purposes; inclusion does not imply endorsement of the vendors, manufacturers, or products by the Centers for Disease Control and Prevention or the US Department of Health and Human Services.
To receive email updates about COVID-19, enter your email address: